Abstract:Introduction: Sickle Cell Disease (SCD) is an inflammatory and vaso-occlusive pathology. Multiple lipid mediators: resolvins, protectins and maresins, collectively known as Specialized Pro-resolving Mediators (SPMs), that are biosynthesized from Omega-3-PolyUnsaturated Fatty Acids (O3PUFAs), docosahexaenoic acid and eicosapentaenoic acid, appear to play a role in the resolution of inflammation. In a recent study, we have documented the presence of SPMs including Resolvin-D1 (RvD1), 17R-RvD3, and their pathway markers in plasma from both children with SCD and age-and race-matched controls with a significant increase in RvD1 levels noted in plasma from children with SCD. In an SCD mouse model exposed to hypoxia/reoxygenation, a previous study has shown that oral administration of 17R-RvD1, the longer acting isomer of RvD1, promotes resolution of SCD-associated inflammation and tissue damage. Objectives: We assessed whether there were any associations in children with SCD between baseline plasma levels of RvD1 and either markers of inflammation, endothelial activation and hemolysis or SCD-related clinical correlates. Methods: Multiplex assays were employed to assess endothelial activation markers (soluble adhesion molecules VCAM-1, ICAM-1 and E-selectin), and inflammatory cytokines (IL-1β, IL-4, IL-6, IL-10, TNF-α and CRP) in plasma. A 3-year retrospective review of individual SCD patient records was performed, and the number of painful episodes of vaso-occlusion or VOC, including those complicated by the occurrence of acute chest syndrome (ACS) were recorded. Total cumulative painful episodes over a 3-year period were included in the analysis. Spearman Rank Correlation was employed to assess the association between two variables. Results: Consistent with the published results, levels of endothelial activation markers (soluble VCAM-1 and soluble E-selectin), cytokines (IL-4, IL-6 and TNF-α), CRP and LDH were increased in SCD plasma compared to controls (Table-1). No significant associations were found in SCD between RvD1 or other lipid mediators and markers of endothelial activation or inflammation (Table-2). However, there were two significant associations noted between 5-HEPE and IL-1β, and between 12-HETE and IL-6. Plasma levels of the hemolytic marker LDH positively correlated with PGE2, TxB2, 7-HDHA, 5-HEPE and 5-HETE (Table-2). Review of medical history revealed 33 of 45 subjects (73%) had at least one VOC episode, and 17 (38%) had at least one ACS episode in the past 3 years. Subjects who had at least one ACS episode in the past 3 years also reported at least one VOC episode during the same period. There was no statistically significant difference in the RvD1 level by VOC [median RvD1 (ng/ml) of 0.056 in VOC -ve sub-group (n=12) vs 0.084 in VOC +ve sub-group (n=33), p=0.748] or ACS history [median RvD1 (ng/ml) of 0.060 in ACS -ve sub-group (n=28) vs 0.104 in ACS +ve sub-group (n=17), p=0.256]. There was no statistically significant association between levels of RvD1 and the total number of VOC/ACS in the past 3 years (correlation coefficient = -0.06, p=0.694). Summary and Conclusions: Because of the documented pro-resolving and anti-inflammatory effects of orally administered 17R-RvD1 in a mouse model of SCD, and elevated basal plasma levels of RvD1 in children with SCD, we investigated whether endogenous RvD1 provides protection against inflammation and clinical complications in SCD children. Other lipid mediators, which were synthesized from O3PUFAs and arachidonic acid, present in increased levels in SCD plasma and potentially involved in modulation of inflammation were also included in the analysis. Unlike in SCD mouse model in which exogenous RvD1 exerted anti-inflammatory effect in ex-vivo experiments and orally administered 17R-RvD1 promoted resolution of inflammation and down-regulated adhesion molecule expression and cytokine production, endogenous RvD1 did not show any significant association with markers of inflammation and endothelial activation or clinical correlates in a small group of SCD children under healthy condition. No significant findings were noted with other lipid mediators. Whether these lipid mediators modulate inflammation during crisis, pre- or post-crisis clinical conditions and whether their production is different during these clinical conditions compared to steady state healthy condition require further investigation.

Adiposity associates with lower plasma resolvin E1 (Rve1): a population study

Omega-3 Polyunsaturated Fatty Acids with Adipose Tissue Inflammation: Longitudinal Analysis in the PROMISE Cohort

An integrative approach to investigate the association among high-sensitive C-reactive protein, body fat mass distribution, and other cardiometabolic risk factors in young healthy women.

Metabolomic Profiles of Plasma Retinol-Associated Dyslipidemia in Men and Women.

Sex differences in lipid mediators derived from omega-3 fatty acids in older individuals with low-grade chronic inflammation

Resolvins, Specialized Proresolving Lipid Mediators, and Their Potential Roles in Metabolic Diseases

Resolvin-D1 (RvD1) and Its Association with Markers of Inflammation, Endothelial Activation, Hemolysis and Clinical Correlates in Children with Sickle Cell Disease (SCD)

Adipokines and incident venous thromboembolism: The Multi-Ethnic Study of Atherosclerosis

Regression of human coronary artery plaque is associated with a high ratio of (18-hydroxy-eicosapentaenoic acid + resolvin E1) to leukotriene B4

Specialized proresolving lipid mediators in humans with the metabolic syndrome after n-3 fatty acids and aspirin

Resolvin D2 prevents vascular remodeling, hypercontractility and endothelial dysfunction in obese hypertensive mice through modulation of vascular and proinflammatory factors

Precursors of specialized pro-resolving mediators (SPMs) are decreased in hypertension, and treatment with SPMs improve vascular relaxation via formyl peptide-receptor-2

Associations of Adipokine Levels With Levels of Remnant Cholesterol: The Multi-Ethnic Study of Atherosclerosis

Specialized Pro-resolving Mediator Improves Vascular Relaxation via Formyl Peptide Receptor-2

A randomized controlled trial of the effects of n-3 fatty acids on resolvins in chronic kidney disease

Plasma Lipidomic Profiling in Patients with Rheumatoid Arthritis

Inflammation-related plasma protein levels and association with adiposity measurements in young adults

Plasma lipoxin A4 and resolvin D1 are not associated with reduced adenoma risk in a randomized trial of aspirin to prevent colon adenomas

Identification of specialized pro-resolving mediator clusters from healthy adults after intravenous low-dose endotoxin and omega-3 supplementation: a methodological validation

Exercise-stimulated Resolvin Biosynthesis in Adipose Tissue is Abrogated by High Fat Diet-induced Adrenergic Deficiency

P168 Specialized pro-resolving lipid mediator Resolvin D1 and omega 6 dihomo-γ-linolenic acid are unable to solve inflammation in the creeping fat of patients with severe postoperative recurrence in Crohn's disease